ConductScience.org, home

Trial · NCT00566995

Adverse events148

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherALT, SGPT (serum glutamic pyruvic transaminase)Metabolism and nutrition disordersVandetanib in Participants With Kidney Cancer243775
otherAST, SGOT(serum glutamic oxaloacetic transaminase)Metabolism and nutrition disordersVandetanib in Participants With Kidney Cancer173737
otherAlbumin, serum-low (hypoalbuminemia)Metabolism and nutrition disordersVandetanib in Participants With Kidney Cancer173733
otherAlkaline phosphataseMetabolism and nutrition disordersVandetanib in Participants With Kidney Cancer133726
otherAllergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)Immune system disordersVandetanib in Participants With Kidney Cancer3373
otherAnorexiaGastrointestinal disordersVandetanib in Participants With Kidney Cancer2372
otherAtelectasisRespiratory, thoracic and mediastinal disordersVandetanib in Participants With Kidney Cancer1371
otherBicarbonate, serum-lowMetabolism and nutrition disordersVandetanib in Participants With Kidney Cancer6376
otherBilirubin (hyperbilirubinemia)Metabolism and nutrition disordersVandetanib in Participants With Kidney Cancer5378
otherCPK (creatine phosphokinase)Metabolism and nutrition disordersVandetanib in Participants With Kidney Cancer153731
otherCalcium, serum-high (hypercalcemia)Metabolism and nutrition disordersVandetanib in Participants With Kidney Cancer6379
otherCalcium, serum-low (hypocalcemia)Metabolism and nutrition disordersVandetanib in Participants With Kidney Cancer73714
otherCardiac Arrhythmia - Other (Specify, __)Cardiac disordersVandetanib in Participants With Kidney Cancer1372
otherCholecystitisHepatobiliary disordersVandetanib in Participants With Kidney Cancer1371
otherConstipationGastrointestinal disordersVandetanib in Participants With Kidney Cancer3373
otherConstitutional Symptoms - Other (Specify, extreme hunger and jitterness)General disordersVandetanib in Participants With Kidney Cancer1371
otherCoughRespiratory, thoracic and mediastinal disordersVandetanib in Participants With Kidney Cancer6377
otherCreatinineMetabolism and nutrition disordersVandetanib in Participants With Kidney Cancer263770
otherCystitisRenal and urinary disordersVandetanib in Participants With Kidney Cancer2372
otherDermatology/Skin - Other (Specify, __)Skin and subcutaneous tissue disordersVandetanib in Participants With Kidney Cancer1371

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00566995/events